Wang Tian-zhan1,
Huo Qing-ping1 
,
Wang Bing1,
Wang Wen-jian2,
Fu Xiao-dong2,
He Yan-ming3,
Wang Yu-xin1,
Peng Wen-bo1,
Liang Fang1,
Meng Sheng-xi1,
Zhang Hong-yan1
For correspondence:- Huo Qing-ping Email: huoqingping005@163.com
Accepted: 27 December 2018 Published: 31 January 2019
Citation: Tian-zhan W, Qing-ping H, Bing W, Wen-jian W, Xiao-dong F, Yan-ming H, et al. Synergistic effects of Yiqi Huazhuo Gushen herbal formula and valsartan on metabolic syndrome complicated with microalbuminuria. Trop J Pharm Res 2019; 18(1):101-108 doi: 10.4314/tjpr.v18i1.15
© 2019 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To study the effects of a combination of Yiqi Huazhuo Gushen formula and valsartan on metabolic syndrome (MetS) complicated with microalbuminuria.
Methods: Patients with MetS (100), recruited from Department of the Traditional Chinese Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital; Department of Integrated Traditional Chinese and Western Medicine, Huashan Hospital, Fudan University; and Department of Endocrinology, Hospital of Integrated Traditional Chinese and Western Medicine in Yueyang, Shanghai University of Traditional Chinese Medicine, were randomly divided into two sets: control group (n = 50) given valsartan treatment, and Chinese herbal medicine (CHF) group (n = 50) given Yiqi Huazhuo Gushen formula in addition to valsartan. Both therapeutic regimens were given once a day for 12 weeks. The parameters measured were conversion rate of microalbuminuria (MA), ratio of urinary albumin to creatinine (UACR), 24- h total volume of urinary protein (24hTP), urinary transferrin, urinary β2 microglobulin, constitutional index (CI), and waist-hip ratio (WHR). Other indices assessed were peak systolic and diastolic pressure (SBP and DBP), mean arterial blood pressure (MABP), fasting plasma glucose (FPG), postprandial 2 h blood glucose (2hPG), glycosylated hemoglobin (GH), steady-state model for insulin resistance (HOMA-IR), total cholesterol (TC), glycerin trilaurate (TG), low density lipoprotein (LDL), and high-density lipoprotein (HDL).
Results: All 100 subjects completed the clinical study. The outcome revealed that compared with 10.00 % in controls, the negative conversion of MA reached 28.00 % in the CHF group (p < 0.050). CHF produced reductions in MA, UACR, BMI, 24hTP and urinary β2 microglobulin (p < 0.05). It also led to marked increases in BMI, WHR, SBP, MAP, FPG, 2hPPG, HbA1c and HOMA-IR, and significant decreases in TG (p < 0.05).
Conclusion: These results suggest that CHF treatment results in alleviation of microalbuminuria and multiple cardiovascular risk factors in metabolic syndrome complicated with microalbuminuria. These effects correlate with improvements in insulin sensitivity and rectification of abnormal fat distribution.
Archives
News Updates
Fulltext in PDF